Josh Enomoto

Josh Enomoto

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Overlook Novavax at the Risk of Incurring an Opportunity Cost

Although Pfizer and Moderna have stolen the headlines, there are still ample opportunities for upside with NVAX stock.

It’s Time for iBio Speculators to Consider Something Else

One of the more intriguing high-risk, high-reward ideas in the Covid-19 space, IBIO stock had an opportunity to distinguish itself. But with the vaccine race heating up, the dangers outweigh the possibilities.

Exxon Mobil Is Breathing Through Temporary Air Pockets

As a transition in power suggests a return to political normalcy, XOM stock and other oil names have jumped higher. However, the broader trend continues to cast a dark cloud over the traditional energy sector.

Pfizer, Moderna Lead the Vaccine Race: Here’s Where 7 Other Top Vaccine Stocks Stand

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here’s how this affects other Covid-19-related biotech stocks.

If You Must Trade Hertz, Always Buy on Tuesday

For nearly everyone, Hertz stock is something you shouldn’t even think about. However, for the rare and intrepid few, HTZGQ could possibly make a case for stakeholder profitability.